Search

Your search keyword '"Lynde, Charles"' showing total 955 results
Start Over Author "Lynde, Charles"
955 results on '"Lynde, Charles"'

4. Maintenance of Investigators Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis.

Author

Eichenfield, Lawrence, Stein Gold, Linda, Lynde, Charles, Guenther, Lyn, Greenberger, Shoshana, Chu, Chia-Yu, Ghodsi, Zara, Vlahos, Bonnie, Sanders, Paul, Cha, Amy, and Canosa, Juliana

Subjects
Adults, Anti-inflammatory agents, Atopic dermatitis, Crisaborole, Disease control, Flare, Investigator’s Static Global Assessment, Maintenance, Pediatrics
Abstract

INTRODUCTION: Treatments for atopic dermatitis (AD) often fail to achieve lasting disease control. In the CrisADe CONTROL phase III study (ClinicalTrials.gov: NCT04040192), participants aged ≥ 3 months with mild to moderate AD treated with once-daily (QD) crisaborole, following initial treatment success with crisaborole twice daily (BID), had longer periods of flare-free maintenance, a higher number of flare-free days, and a lower number of flares compared with those who received vehicle. The study was an exploratory analysis of data on the maintenance of response per Investigators Static Global Assessment (ISGA; ISGA score of 0 [clear] or 1 [almost clear]) during the CrisADe CONTROL study through week 52. METHODS: Exploratory endpoints were the time to ISGA response during the open-label run-in period, and the maintenance of ISGA response and the severity and duration of flares during the double-blind maintenance period. Outcomes were stratified by age (participants aged 3 months to

Published
2024

5. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry

Author

Papp, Kim A., Gooderham, Melinda, Lynde, Charles, Brassard, Danielle, Al-Mohammedi, Faisal, Prajapati, Vimal H., Delorme, Isabelle, Albrecht, Lorne, Haydey, Richard, Alam, Maryam Shayesteh, Beecker, Jennifer, Siddha, Sanjay, Maguin, Marie, Farag, Mahmoud S., Vieira, Antonio, Rihakova, Lenka, and Langley, Richard G.

Published
2024
Full Text
View/download PDF

6. A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata

Author

King, Brett, Zhang, Xingqi, Harcha, Walter Gubelin, Szepietowski, Jacek C, Shapiro, Jerry, Lynde, Charles, Mesinkovska, Natasha A, Zwillich, Samuel H, Napatalung, Lynne, Wajsbrot, Dalia, Fayyad, Rana, Freyman, Amy, Mitra, Debanjali, Purohit, Vivek, Sinclair, Rodney, and Wolk, Robert

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Humans, Adult, Adolescent, Alopecia Areata, Carbazoles, Tryptamines, Protein Kinase Inhibitors, Immunologic Factors, adolescents, alopecia areata, hair loss, ritlecitinib, Immunology, Pharmacology and Pharmaceutical Sciences, Oncology and carcinogenesis
Abstract

What is this summary about?This is a summary of the results of the ALLEGRO phase 2b/3 clinical trial, originally published in The Lancet. ALLEGRO-2b/3 looked at how well and safely the study medicine, ritlecitinib, works in treating people with alopecia areata ('AA' for short). The immune system protects your body from outside invaders such as bacteria and viruses. AA is an autoimmune disease, meaning a disease in which one's immune system attacks healthy cells of the body by mistake. In AA, the immune system attacks hair follicles, causing hair to fall out. AA causes hair loss ranging from small bald patches to complete hair loss on the scalp, face, and/or body. Ritlecitinib is a medicine taken as a pill every day, by mouth, that is approved for the treatment of severe AA. It blocks processes that are known to play a role in causing hair loss in patients with AA.What were the results of the study?Adults and adolescents (12 years and older) took part in the ALLEGRO-2b/3 study. They either took ritlecitinib for 48 weeks or took a placebo (a pill with no medicine) for 24 weeks. Participants taking placebo later switched to taking ritlecitinib for 24 weeks. The study showed that participants taking ritlecitinib had more hair regrowth on their scalp after 24 weeks than those taking the placebo. Hair regrowth was also seen on the eyebrows and eyelashes in participants taking ritlecitinib. Hair regrowth continued to improve to week 48 with continued ritlecitinib treatment. In addition, more participants taking ritlecitinib reported that their AA had 'moderately' or 'greatly' improved after 24 weeks than those taking the placebo. Similar numbers of participants taking ritlecitinib or placebo had side effects after 24 weeks. Most side effects were mild or moderate.What do the results of the study mean?Ritlecitinib was an effective and well-tolerated treatment over 48 weeks for people with AA. Clinical Trial Registration: NCT03732807 (phase 2b/3 ALLEGRO study).

Published
2023

7. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial

Author

King, Brett, Zhang, Xingqi, Harcha, Walter Gubelin, Szepietowski, Jacek C, Shapiro, Jerry, Lynde, Charles, Mesinkovska, Natasha A, Zwillich, Samuel H, Napatalung, Lynne, Wajsbrot, Dalia, Fayyad, Rana, Freyman, Amy, Mitra, Debanjali, Purohit, Vivek, Sinclair, Rodney, and Wolk, Robert

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Humans, Adult, Male, Female, Adolescent, Treatment Outcome, Alopecia Areata, COVID-19, Protein Kinase Inhibitors, Double-Blind Method, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundAlopecia areata is characterised by non-scarring loss of scalp, face, or body hair. We investigated the efficacy and safety of ritlecitinib, an oral, selective dual JAK3/TEC family kinase inhibitor, in patients with alopecia areata.MethodsIn this randomised, double-blind, multicentre, phase 2b-3 trial done at 118 sites in 18 countries, patients aged 12 years and older with alopecia areata and at least 50% scalp hair loss were randomly assigned to oral ritlecitinib or placebo once-daily for 24 weeks, with or without a 4-week loading dose (50 mg, 30 mg, 10 mg, 200 mg loading dose followed by 50 mg, or 200 mg loading dose followed by 30 mg), followed by a 24-week extension period during which ritlecitinib groups continued their assigned doses and patients initially assigned to placebo switched to ritlecitinib 50 mg or 200 mg loading dose followed by 50 mg. Randomisation was done by use of an interactive response system and was stratified by baseline disease severity and age. The sponsor, patients, and investigators were masked to treatment, and all patients received the same number of tablets to maintain masking. The primary endpoint was Severity of Alopecia Tool (SALT) score 20 or less at week 24. The primary endpoint was assessed in all assigned patients, regardless of whether they received treatment. This study was registered with ClinicalTrials.gov, NCT03732807.FindingsBetween Dec 3, 2018, and June 24, 2021, 1097 patients were screened and 718 were randomly assigned to receive ritlecitinib 200 mg + 50 mg (n=132), 200 mg + 30 mg (n=130), 50 mg (n=130), 30 mg (n=132), 10 mg (n=63), placebo to 50 mg (n=66), or placebo to 200 mg + 50 mg (n=65). 446 (62%) of 718 patients were female and 272 (38%) were male. 488 (68%) were White, 186 (26%) were Asian, and 27 (4%) were Black or African American. Of 718 patients randomly assigned, 104 patients discontinued treatment (34 withdrew, 19 adverse events [AEs], 12 physician decision, 12 lack of efficacy, 13 lost to follow up, five rolled over to long-term study transfer, four pregnancies, two protocol deviations, one declined to attend follow-up due to COVID-19, one attended last visit very late due to COVID-19, and one non-compliance). At week 24, 38 (31%) of 124 patients in the ritlecitinib 200 mg + 50 mg group, 27 (22%) of 121 patients in the 200 mg + 30 mg group, 29 (23%) of 124 patients in the 50 mg group, 17 (14%) of 119 patients in the 30 mg group, and two (2%) of 130 patients in the placebo group had a response based on SALT score 20 or less. The difference in response rate based on SALT score 20 or less between the placebo and the ritlecitinib 200 mg + 50 mg group was 29·1% (95% CI 21·2-37·9; p

Published
2023

8. Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials

Author

Silverberg, Jonathan I, Lynde, Charles W, Abuabara, Katrina, Patruno, Cataldo, de Benedetto, Anna, Zhang, Haixin, Thomas, Ryan B, Bégo-Le-Bagousse, Gaëlle, Khokhar, Faisal A, Vakil, Jignesh, Marco, Ainara Rodríguez, and Levit, Noah A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Clinical Research, Aging, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Skin, Humans, Adult, Middle Aged, Aged, Dermatitis, Atopic, Quality of Life, Injections, Subcutaneous, Double-Blind Method, Severity of Illness Index, Randomized Controlled Trials as Topic, Treatment Outcome, Dermatology & Venereal Diseases, Clinical sciences
Abstract

BackgroundAdults aged ≥ 60 years are often underrepresented in atopic dermatitis (AD) clinical trials; age-related comorbidities may impact treatment efficacy and safety.ObjectiveThe aim was to report dupilumab efficacy and safety in patients aged ≥ 60 years with moderate-to-severe AD.MethodsData were pooled from four randomized, placebo-controlled dupilumab trials of patients with moderate-to-severe AD (LIBERTY AD SOLO 1 and 2, LIBERTY AD CAFÉ, and LIBERTY AD CHRONOS) and stratified by age (

Published
2023

11. Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial

Author

Piliang, Melissa, Lynde, Charles, King, Brett, Mirmirani, Paradi, Sinclair, Rodney, Senna, Maryanne, Forman, Seth, Bordone, Lindsey, De La Cueva Dobao, Pablo, Wolk, Robert, Zwillich, Samuel H., Tran, Helen, Wajsbrot, Dalia, Ahmed, Haytham Mohamed, and Takiya, Liza

Published
2025
Full Text
View/download PDF

12. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials

Author

Lynde, Charles, Guenther, Lyn, Sauder, Maxwell, Bissonnette, Robert, Rao, Jaggi, Day, Isaiah, Devani, Alim, Metelitsa, Andrei, Grewal, Parbeer, Molin, Sonja, Ruer-Mulard, Mireille, Giordano-Labadie, Françoise, Maillard, Hervé, Reguiai, Ziad, Bernier, Claire, Leleu, Camille, Seneschal, Julien, Staumont-Sallé, Delphine, Hubiche, Thomas, Jacobzone, Caroline, Khemis, Abdallah, Crépy, Marie-Noëlle, Worm, Margitta, Bauer, Andrea, Sell, Sabine, Ekanayake-Bohlig, Swarna, Pauser, Sylvia, Buhl, Timo, Schwinn, Andreas, Eberlein, Bernadette, Quist, Sven, Bauer, Boris, Peris, Ketty, Rossi, Maria Teresa, Fargnoli, Maria, Naldi, Luigi, Stingeni, Luca, Ferrucci, Silvia, Walecka-Herniczek, Irena, Krasowska, Dorota, Lesiak, Aleksandra, Okuniewska, Aleksandra, Pulka, Grażyna, Dyczek, Malgorzata, Kwiek, Bartlomiej, Czajkowski, Rafal, Myśliwiec, Hanna, Mohandas, Padma, Cliff, Sandeep, Warren, Richard, Cousen, Pippa, Johnston, Graham, Woolf, Richard, Papp, Kim, Adam, David, Toth, Darryl, Hong, Chih-ho, Turchin, Irina, Niakosari, Firouzeh, Poulos, Elena, Rivers, Jason, Ohayon, Jason, Gooderham, Melinda, Tjioe, Milan, Rustemeyer, Thomas, de Bruin-Weller, Marjolein S., Schuttelaar, Marie L.A., Molhoek, Judith, Oosting, Bert, Pinter, Andreas, Kaspari, Markus, Magnolo, Nina, Sebastian, Michael, Thaci, Diamant, Schliemann, Sibylle, Radny, Peter, Leitz, Nicolas, Tsianakas, Athanasios, Yazdi, Amir, Kamstrup, Maria, Sommerlund, Mette, Zachariae, Claus, Owczarek, Witold, Dudra-Jastrzebska, Monika, Reich, Adam, Kowalska-Oledzka, Elzbieta, Szepietowski, Jacek, Poznanska, Maria, Weglowska, Jolanta, Aerts, Olivier, Roquet-Gravy, Pierre-Paul, Lanssens, Sven, Castelijns, Francisca, Scheers, Christelle, Suys, Erwin, Kint, Bernard, Serra-Baldrich, Esther, Carrascosa, José Manuel, de la Cueva Dobao, Pablo, Izu, Rosa, Silvestre, Juan Francisco, Coto-Segura, Pablo, Fernández-Orland, Almudena, Warren, Richard B, Agner, Tove, Schuttelaar, Marie L A, Baranowski, Keith, Korn, Sofie, Kurvits, Merle, Plohberger, Ursula, and Strange Vest, Natacha

Published
2024
Full Text
View/download PDF

14. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis

Author

Weidinger, Stephan, Blauvelt, Andrew, Papp, Kim A., Reich, Adam, Lee, Chih-Hung, Worm, Margitta, Lynde, Charles, Kataoka, Yoko, Foley, Peter, Wei, Xiaodan, Wong, Wanling, Solente, Anne-Catherine, Weber, Christine, Adelman, Samuel, Davey, Sonya, Hurbin, Fabrice, Rynkiewicz, Natalie, Yen, Karl, O’Malley, John T., and Bernigaud, Charlotte

Published
2024
Full Text
View/download PDF

21. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study

Author

Torres, Tiago, Puig, Luis, Vender, Ron, Yeung, Jensen, Carrascosa, José-Manuel, Piaserico, Stefano, Gisondi, Paolo, Lynde, Charles, Ferreira, Paulo, Bastos, Pedro Mendes, Dauden, Esteban, Leite, Luiz, Valerio, Joana, del Alcázar-Viladomiu, Elena, Rull, Eva Vilarrasa, Llamas-Velasco, Mar, Pirro, Federico, Messina, Francesco, Bruni, Manfredo, Licata, Gaetano, Ricceri, Federica, Nidegger, Alessia, Hugo, Jan, Mufti, Asfandyar, Daponte, Athina-Ioanna, Teixeira, Laetitia, Balato, Anna, Romanelli, Marco, Prignano, Francesca, Gkalpakiotis, Spyridon, Conrad, Curdin, Lazaridou, Elizabeth, Rompoti, Natalia, Papoutsaki, Marina, Nogueira, Miguel, and Chiricozzi, Andrea

Published
2022
Full Text
View/download PDF

23. Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel

Author

Papp, Kim A., Melosky, Barbara, Sehdev, Sandeep, Hotte, Sebastien J., Beecker, Jennifer R., Kirchhof, Mark G., Turchin, Irina, Dutz, Jan P., Gooderham, Melinda J., Gniadecki, Robert, Hong, Chih-ho, Lambert, Jo, Lynde, Charles W., Prajapati, Vimal H., and Vender, Ronald B.

Published
2023
Full Text
View/download PDF

25. Age affects drug survival rates of interleukin (IL)‐17 and IL‐23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi‐country, cohort study.

Author

Chiricozzi, Andrea, Coscarella, Giulia, Puig, Luis, Vender, Ron, Yeung, Jensen, Carrascosa, José‐Manuel, Piaserico, Stefano, Gisondi, Paolo, Lynde, Charles, Ferreira, Paulo, Bastos, Pedro Mendes, Dauden, Esteban, Leite, Luiz, Valerio, Joana, del Alcázar‐Viladomiu, Elena, Vilarrasa, Eva, Llamas‐Velasco, Mar, Alessandri‐Bonetti, Mario, Messina, Francesco, and Bruni, Manfredo

Subjects
OLDER patients, PROPORTIONAL hazards models, TERMINATION of treatment, BIOLOGICALS, DRUG analysis
Abstract

Background: Scarce data related to the drug survival of biologic agents in psoriasis patients aged ≥65 years is available. Objectives: To evaluate the drug survival of interleukin (IL)‐23 or the IL‐17 inhibitors approved for the treatment of moderate‐to‐severe psoriasis in elderly patients (aged ≥65 years), compared with younger adult patients (aged <65 years), and to identify clinical predictors that can influence the drug survival. Methods: This retrospective multicentric cohort study included adult patients with moderate‐to‐severe psoriasis, dissecting two‐patient subcohorts based on age: elderly versus younger adults. Kaplan–Meier estimator and proportional hazard Cox regression models were used for drug survival analysis. Results: We included 4178 patients and 4866 treatment courses; 934 were elderly (1072 treatment courses), and 3244 were younger patients (3794 treatment courses). Drug survival, considering all causes of interruption, was higher in patients aged <65 years than in elderly patients overall (log‐rank p < 0.006). This difference was significant for treatment courses involving IL‐23 inhibitors (p < 0.001) but not for those with IL‐17 inhibitors (p = 0.2). According to both uni‐ and multi‐variable models, elder age was associated with an increased risk of treatment discontinuation (univariable analysis: HR: 1.229, 95% CI 1.062–1.422; p < 0.006; multivariable analysis: HR: 1.199, 95% CI 1.010–1.422; p = 0.0377). Anti‐IL‐23 agents were associated with a reduced likelihood of treatment discontinuation after adjusting for other variables (HR: 0.520, 95% CI 0.368–0.735; p < 0.001). Being previously treated with IL‐17 inhibitors increased the probability of discontinuation. Conclusions: Elderly patients with psoriasis have an increased risk of biologic treatment discontinuation compared with younger adult patients, particularly, if being treated with IL‐23 inhibitors. However, in stratified analyses conducted in elderly patients, IL‐23 inhibitors showed higher drug survival rates than IL‐17 inhibitors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial

Author

Blauvelt, Andrew, Silverberg, Jonathan I., Lynde, Charles W., Bieber, Thomas, Eisman, Samantha, Zdybski, Jacek, Gubelin, Walter, Simpson, Eric L., Valenzuela, Fernando, Criado, Paulo Ricardo, Lebwohl, Mark G., Feeney, Claire, Khan, Tahira, Biswas, Pinaki, DiBonaventura, Marco, Valdez, Hernan, Cameron, Michael C., and Rojo, Ricardo

Published
2022
Full Text
View/download PDF

37. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

Author

Torres, Tiago, Puig, Luis, Vender, Ron, Lynde, Charles, Piaserico, Stefano, Carrascosa, Jose M., Gisondi, Paolo, Daudén, Esteban, Conrad, Curdin, Mendes-Bastos, Pedro, Ferreira, Paulo, Leite, Luiz, Lu, Justin D., Valerio, J., Bruni, M., Messina, F., Nidegger, A., Llamas-Velasco, M., del Alcazar, E., Mufti, A., White, Kyra, Caldarola, G., Teixeira, Laetitia, Romanelli, Paolo, Desai, K., Gkalpakiotis, Spyridon, Romanelli, Marco, Yeung, Jensen, Nogueira, Miguel, and Chiricozzi, Andrea

Published
2021
Full Text
View/download PDF

39. Considerations for defining and diagnosing generalized pustular psoriasis.

Author

Prajapati, Vimal H., Lynde, Charles W., Gooderham, Melinda J., Hong, H. Chih‐ho, Kirchhof, Mark G., Lansang, Perla, Ringuet, Julien, Turchin, Irina, Vender, Ron, Yeung, Jensen, and Papp, Kim A.

Subjects
*DELAYED diagnosis, *SYMPTOMS, *DIAGNOSIS, *SKIN diseases, *PSORIASIS, *FIBROMYALGIA
Abstract

Generalized pustular psoriasis (GPP) is a rare, chronic skin disease, characterized by widespread pustules and erythema, often accompanied with systemic signs and symptoms. GPP flares occur episodically but may be protracted. Left untreated, GPP can be life‐threatening. Despite being first reported over 100 years ago, definitions and diagnostic criteria for GPP have been inconsistent and varied due, in part, to its rarity and a limited understanding of its pathogenesis. As such, many patients with GPP face delays in diagnosis and subsequent treatment. This manuscript aims to increase the recognition of GPP and provide foundational considerations to aid in the definition and diagnosis of this disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.

Author

Blauvelt, Andrew, Guttman-Yassky, Emma, Lynde, Charles, Khattri, Saakshi, Schlessinger, Joel, Imafuku, Shinichi, Tada, Yayoi, Morita, Akimichi, Wiseman, Marni, Kwiek, Bartlomiej, Machkova, Martina, Zhang, Peijin, Linaberry, Misti, Li, Jie, Zhang, Sandra, Franchin, Giovanni, Charles, Edgar D., De Oliveira, Claudia H.M.C., and Silverberg, Jonathan I.

Published
2024
Full Text
View/download PDF

43. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea

Author

Schaller, Martin, Kemény, Lajos, Havlickova, Blanka, Jackson, J. Mark, Ambroziak, Marcin, Lynde, Charles, Gooderham, Melinda, Remenyik, Eva, Del Rosso, James, Weglowska, Jolanta, Chavda, Rajeev, Kerrouche, Nabil, Dirschka, Thomas, and Johnson, Sandra

Published
2020
Full Text
View/download PDF

44. Association Between Early Clinical Responses and Long-Term Outcomes With Ruxolitinib Cream Treatment in Mild to Moderate Atopic Dermatitis

Author

Prajapati, Vimal H., primary, Geng, Bob, additional, Blauvelt, Andrew, additional, Eichenfield, Lawrence F., additional, Grewal, Parbeer, additional, Kircik, Leon, additional, Lio, Peter, additional, Lynde, Charles, additional, Simpson, Eric L., additional, Ren, Haobo, additional, Sturm, Daniel, additional, Wong, Grace, additional, and Hong, Chih-ho, additional

Published
2024
Full Text
View/download PDF

45. 498 - Real-world use and effectiveness of upadacitinib in adults and adolescents with atopic dermatitis: preliminary analysis of the real-world multicountry AD-VISE study

Author

Lima, Hermenio, primary, Pereyra-Rodriguez, José-Juan, additional, Beecker, Jennifer, additional, Lynde, Charles W, additional, Sancho, Cristina, additional, Lane, Michael, additional, Wang, Hongwei, additional, Calimlim, Brian M, additional, Armendariz, Yolanda, additional, and Gooderham, Melinda J, additional

Published
2024
Full Text
View/download PDF

46. 523 - Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD)

Author

Weidinger, Stephan, primary, Blauvelt, Andrew, additional, Papp, Kim, additional, Reich, Adam, additional, Lee, Chih-Hung, additional, Worm, Margitta, additional, Lynde, Charles, additional, Kataoka, Yoko, additional, Foley, Peter, additional, Weber, Christine, additional, Wong, Wanling, additional, Hurbin, Fabrice, additional, Rynkiewicz, Natalie, additional, Yen, Karl, additional, Wei, Xiaodan, additional, O’Malley, John T, additional, and Bernigaud, Charlotte, additional

Published
2024
Full Text
View/download PDF

48. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials

Author

Bissonnette, Robert, Warren, Richard B, Pinter, Andreas, Agner, Tove, Gooderham, Melinda, Schuttelaar, Marie L A, Crépy, Marie-Noëlle, Stingeni, Luca, Serra-Baldrich, Esther, Baranowski, Keith, Korn, Sofie, Kurvits, Merle, Plohberger, Ursula, Strange Vest, Natacha, Schliemann, Sibylle, Lynde, Charles, Guenther, Lyn, Sauder, Maxwell, Bissonnette, Robert, Rao, Jaggi, Day, Isaiah, Devani, Alim, Metelitsa, Andrei, Grewal, Parbeer, Molin, Sonja, Ruer-Mulard, Mireille, Giordano-Labadie, Françoise, Maillard, Hervé, Reguiai, Ziad, Bernier, Claire, Leleu, Camille, Seneschal, Julien, Staumont-Sallé, Delphine, Hubiche, Thomas, Jacobzone, Caroline, Khemis, Abdallah, Crépy, Marie-Noëlle, Worm, Margitta, Bauer, Andrea, Sell, Sabine, Ekanayake-Bohlig, Swarna, Pauser, Sylvia, Buhl, Timo, Schwinn, Andreas, Eberlein, Bernadette, Quist, Sven, Bauer, Boris, Peris, Ketty, Rossi, Maria Teresa, Fargnoli, Maria, Naldi, Luigi, Stingeni, Luca, Ferrucci, Silvia, Walecka-Herniczek, Irena, Krasowska, Dorota, Lesiak, Aleksandra, Okuniewska, Aleksandra, Pulka, Grażyna, Dyczek, Malgorzata, Kwiek, Bartlomiej, Czajkowski, Rafal, Myśliwiec, Hanna, Mohandas, Padma, Cliff, Sandeep, Warren, Richard, Cousen, Pippa, Johnston, Graham, Woolf, Richard, Papp, Kim, Adam, David, Toth, Darryl, Hong, Chih-ho, Turchin, Irina, Niakosari, Firouzeh, Poulos, Elena, Rivers, Jason, Ohayon, Jason, Gooderham, Melinda, Tjioe, Milan, Rustemeyer, Thomas, de Bruin-Weller, Marjolein S., Schuttelaar, Marie L.A., Molhoek, Judith, Oosting, Bert, Pinter, Andreas, Kaspari, Markus, Magnolo, Nina, Sebastian, Michael, Thaci, Diamant, Schliemann, Sibylle, Radny, Peter, Leitz, Nicolas, Tsianakas, Athanasios, Yazdi, Amir, Kamstrup, Maria, Sommerlund, Mette, Zachariae, Claus, Owczarek, Witold, Dudra-Jastrzebska, Monika, Reich, Adam, Kowalska-Oledzka, Elzbieta, Szepietowski, Jacek, Poznanska, Maria, Weglowska, Jolanta, Aerts, Olivier, Roquet-Gravy, Pierre-Paul, Lanssens, Sven, Castelijns, Francisca, Scheers, Christelle, Suys, Erwin, Kint, Bernard, Serra-Baldrich, Esther, Carrascosa, José Manuel, de la Cueva Dobao, Pablo, Izu, Rosa, Silvestre, Juan Francisco, Coto-Segura, Pablo, and Fernández-Orland, Almudena

Abstract

Chronic hand eczema is a fluctuating, inflammatory, pruritic, often painful disease of hands and wrists that strongly impacts quality of life and occupational capabilities of patients. The aim of phase 3 DELTA 1 and DELTA 2 was to assess the efficacy and safety of twice-daily applications of the topical pan-Janus kinase inhibitor delgocitinib cream 20 mg/g versus cream vehicle in adults with moderate to severe chronic hand eczema.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results